Author Archives: Warren Woessner

Mallinckrodt v. Praxair – Innomax Method Patent Fails Alice/Mayo Test

On Tuesday, a Delaware district court judge ruled that a group of Mallinckrodt patents failed the Alice/(mostly)Mayo test as claiming a natural phenomenon. The patents are directed to a method of safely using the Innomax system, which administers nitric oxide to infants … Continue reading

Posted in Patent Eligible Subject Matter | 1 Comment

Should the Australian Patent Office be denying patent eligibility to cDNA inventions?

This is a guest post from Grant Shoebridge of Shelston IP. In this, the first of a trilogy of articles investigating specific areas of Australian Patent Office examination practice, I consider how the High Court’s decision in D’Arcy v Myriad Genetics Inc … Continue reading

Posted in Australian Practice, BIO | Leave a comment

New Webinar Series: Practical IP for Natural Sciences

Please join us in a new webinar series directed to the practical strategies in a new era of patent law to protect IP in chemistry, pharmaceuticals, biotechnology and genetic medicine. The collision of new technologies and patent statutes of a … Continue reading

Posted in Webinar | Tagged , , , , , , | Leave a comment

Athena Diagnostics, Inc. v. Mayo (D. Mass., August 4, 2017) – “That’s all,” She Wrote.

Please read my recent post about stage 1 of this proceeding, in which the Judge in 2016 found that the claims to diagnosing Myasthemia Gravis (MG) by adding MuSk to a patient sample and detecting any IgG autoantibody complexes that … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment